New Stock News | Jingze Biotech's Hong Kong Stock IPO Prospectus Invalid
Jingze Biopharma (Hefei) Co., Ltd. (referred to as Jingze Biopharma), submitted its Hong Kong stock prospectus on June 27, which expired after six months on December 27.
Jingze Biomedical (Hefei) Co., Ltd. (referred to as "Jingze Biomedical") submitted its Hong Kong stock prospectus on June 27, which expired after 6 months on December 27. At the time of submission, CICC and Guoyuan International were its joint sponsors.
According to the previously disclosed prospectus, Jingze Biomedical is a biopharmaceutical company focused on two high-growth tracks of assisted reproductive drugs and ophthalmic drugs. Guided by unmet clinical needs, the company has established a comprehensive research and development system and commercial-scale production capacity. With its systemic capabilities, the company independently developed multiple product pipelines and has advanced many high-tech barrier drugs with great commercial prospects to late-stage clinical trials and commercialization.
Related Articles
ZGC TEC LEASING (01601) entered into a financing lease agreement for the production equipment of backlight sources.
CARSGEN-B (02171) spent 4.8477 million Hong Kong dollars to repurchase 32,600 shares on December 29th.
JINMA ENERGY (06885): Rao Chaohui appointed as Chairman of the Nominating Committee and member of the Strategic Development Committee.
ZGC TEC LEASING (01601) entered into a financing lease agreement for the production equipment of backlight sources.
CARSGEN-B (02171) spent 4.8477 million Hong Kong dollars to repurchase 32,600 shares on December 29th.
JINMA ENERGY (06885): Rao Chaohui appointed as Chairman of the Nominating Committee and member of the Strategic Development Committee.
